Evidence map›Paper›PMID 40191655›Full record

ArticleNAR cancer2025

Identification of FLYWCH1 as a regulator of platinum-resistance in epithelial ovarian cancer.

Tabea L Fullstone, Helene Rohm, Till Kaltofen, Sophia Hierlmayer, Juliane Reichenbach, Simon Schweikert, Franziska Knodel, Ann-Kathrin Loeffler, Doris Mayr, Udo Jeschke and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tabea L FullstoneDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.ORCID 0000-0002-1582-442X
Helene RohmDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.
Till KaltofenDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Sophia HierlmayerDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Juliane ReichenbachDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Simon SchweikertDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.
Franziska KnodelDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.
Ann-Kathrin LoefflerDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.
Doris MayrInstitute of Pathology, LMU Munich, 81377 Munich, Germany.
Udo JeschkeDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Sven MahnerDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Mirjana KesslerDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-9879-1052
Fabian TrillschDepartment of Obstetrics and Gynaecology, University Hospital, LMU Munich, 81377 Munich, Germany.
Philipp RathertDepartment of Molecular Biochemistry, Institute of Biochemistry, University of Stuttgart, 70569 Stuttgart, Germany.ORCID 0000-0003-1477-136X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum-based combination chemotherapy remains the backbone of first-line treatment for patients with advanced epithelial ovarian cancer (EOC). While most patients initially respond well to the treatment, patients with relapse ultimately develop platinum resistance. This study identified FLYWCH-type zinc finger-containing protein 1 (FLYWCH1) as an important regulator in the resistance development process. We showed that the loss of FLYWCH1 promotes platinum resistance in EOC cells, and the low FLYWCH1 expression is correlated with poor prognosis of EOC patients. In platinum-sensitive cells, FLYWCH1 colocalizes with H3K9me3, but this association is significantly reduced when cells acquire resistance. The suppression of FLYWCH1 induces gene expression changes resulting in the deregulation of pathways associated with resistance. In line with its connection to H3K9me3, FLYWCH1 induces gene silencing in a synthetic reporter assay and the suppression of FLYWCH1 alters H3K9me3 at promoter regions and repeat elements. The loss of FLYWCH1 leads to the derepression of LTR and Alu repeats, thereby increasing transcriptional plasticity and driving the resistance development process. Our data highlight the importance of FLYWCH1 in chromatin biology and acquisition of platinum resistance through transcriptional plasticity and propose FLYWCH1 as a potential biomarker for predicting treatment responses in EOC patients.

Indexed as

Carcinoma, Ovarian EpithelialDrosophila ProteinsDrug Resistance, NeoplasmNeoplasms, Glandular and EpithelialOvarian NeoplasmsAntineoplastic AgentsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHistonesHumansPlatinumPrognosisPromoter Regions, GeneticAntineoplastic AgentsDrosophila ProteinsHistonesPlatinum

Identifiers

PMID40191655
PMCPMC11970373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.